Effect of ANKASCIN 568-P Products Regulating Blood Lipid- A Double-blind, Placebo-controlled Clinical Research
This study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (24 weeks in total), divided into three periods (screening, treatment, and discontinuation follow-up)
• Male or Female women over the age of 20 (women of childbearing age should not be pregnant or breastfeeding during the study period).
• A sane and communicative adult.
• 18≦BMI≦35.
• Sub-healthy people with simple dyslipidemia and those who have been judged by the doctor that they do not need to take hypolipidemic drugs for the time being, or those who insist on not taking drugs.
• Screening criteria Low-density lipoprotein cholesterol (LDL-C): 130\
⁃ 190 mg/dL. screening criteria and high-density lipoprotein cholesterol (HLDL-C): below 50 mg/dL.
• Those without other serious diseases (cancer, heart failure, diabetes, myocardial infarction, liver cirrhosis, moderate to severe liver and kidney dysfunction, stroke, etc.).
• During the experiment, the daily routine and eating habits should be maintained and not changed deliberately.